Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Antisoma PLC (~292)

  Print      Mail a friend       Annual reports

Tuesday 08 January, 2002

Antisoma PLC


Antisoma PLC
8 January 2002

          Antisoma appoints Lloyd Kelland as Head of Laboratory

London, 8 January 2002 - Antisoma plc (LSE:ASM, NASD:ASOM),  the UK-based
biopharmaceutical company specialising in the development of products for the
treatment of cancer, today announces the appointment of Dr Lloyd Kelland as
Head of Laboratory.

Dr Kelland, joins Antisoma from the UK's Cancer Research Campaign (CRC) Centre
for Cancer Therapeutics, Institute of Cancer Research, London, where he was
Reader/Associate Professor and head of drug evaluation.  Dr Kelland is an
internationally recognised authority in the fields of platinum and other small
molecule anti-cancer agents.

In his new role he will oversee academic and other collaborations linked to
Antisoma's rapidly expanding pre-clinical pipeline.  The Company currently has
four products in clinical trials and five at the pre-clinical stage as well as
a number of highly innovative research programmes.

Dr Kelland, 43, has a degree in Pharmacy and a PhD and Doctor of Science from
the University of Bath, England.  His studies at the CRC Centre for Cancer
Therapeutics have included extensive work on platinum complexes, including
drugs subsequently licensed to Bristol Myers Squibb and AstraZeneca.  He
organised the Eighth International Symposium on Platinum Complexes in 1999 and
is co-author of the book Platinum-based Drugs in Cancer Therapy, published in
2000.  He has recently worked on collaborations linked to the inhibition of
telomerase, farnesyl transferase and various kinases.  Dr Kelland is
vice-chair of the Screening and Pharmacology Group of the European
Organisation for the Research and Treatment of Cancer (EORTC), a member of the
EORTC Laboratory liaison committee and sits on the Editorial Board of the
European Journal of Cancer and Cancer Chemotherapy Pharmacology.  Dr Kelland
is the author or co-author of over 140 peer-reviewed publications.

Glyn Edwards, Antisoma's Chief Executive Officer, commented:

'Lloyd Kelland's appointment reflects the significant and continuing expansion
of Antisoma's pipeline.  We now have four clinical and five pre-clinical
projects.  We also have a highly active in-licensing programme which has
resulted in the acquisition in the past few months of DMXAA, a vascular
targeting agent, and TheraNase, now part of our targeted apoptosis programme.
Dr Kelland brings invaluable expertise and experience to Antisoma at an
important stage of our development.'

- ENDS -


Antisoma plc
Glyn Edwards, Chief Executive Officer           Tel: +44 (0)20 8799 8200

Financial Dynamics
Melanie Toyne Sewell/ Fiona Noblet              Tel: +44 (0)20 7831 3113

Except for the historical information presented, certain matters discussed in
this statement are forward looking statements that are subject to a number of
risks and uncertainties that could cause actual results to differ materially
from results, performance or achievements expressed or implied by such
statements. These risks and uncertainties may be associated with product
discovery and development, including statements regarding the company's
clinical development programmes, the expected timing of clinical trials and
regulatory filings. Such statements are based on management's current
expectations, but actual results may differ materially.

Notes to Editors


Antisoma is a biopharmaceutical company developing novel products for the
treatment of cancer.  Using its drug development experience, the Company aims
to produce safer and more effective tumour targeting therapies for
commercialisation by pharmaceutical partners.  Antisoma acquires the rights to
promising new product candidates through partnerships with internationally
recognised academic or cancer research institutions.  These include the lead
product candidate, pemtumomab, which was licensed from the Imperial Cancer
Research Fund and is currently in a Phase III study as adjuvant treatment for
ovarian cancer, with designated Orphan Drug status in the US and EU.  There
are three additional products in the clinical pipeline, Therex, DMXAA and
TheraFab, and several pre-clinical programmes of which two, Angiomab and
Thioplatin, are expected to enter clinical studies in 2002.  Visit for further information about Antisoma.


a d v e r t i s e m e n t